Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial

[1]  P. Neven,et al.  PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial. , 2023, European journal of cancer.

[2]  D. Berton,et al.  Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial , 2023, JCO precision oncology.

[3]  Rebecca A Dagg,et al.  Targeting DNA damage response pathways in cancer , 2022, Nature Reviews Cancer.

[4]  A. Vincent-Salomon,et al.  Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial. , 2022, JAMA oncology.

[5]  F. Bidard,et al.  Expanding biomarkers for PARP inhibitors , 2022, Nature Cancer.

[6]  Hsin-Ta Wu,et al.  A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes , 2022, Nature Cancer.

[7]  C. Genestie,et al.  2022-RA-935-ESGO Development of an academic genomic instability score for ovarian cancers , 2022, Ovarian cancer.

[8]  C. Genestie,et al.  2022-RA-567-ESGO The Geneva HRD test: clinical validation on 469 samples from the PAOLA-1 trial , 2022, Ovarian cancer.

[9]  M. Tiemann,et al.  2022-RA-873-ESGO Validation study of the ‘NOGGO-GIS ASSAY’ based on ovarian cancer samples from the first-line PAOLA-1/ENGOT-ov25 phase-III trial , 2022, Pathology.

[10]  I. Vergote,et al.  2022-RA-913-ESGO Clinical performance evaluation of a novel deep learning solution for homologous recombination deficiency detection , 2022, Ovarian cancer.

[11]  I. Ray-Coquard,et al.  LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) , 2022, Annals of Oncology.

[12]  G. Lou,et al.  Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial (LBA 5) , 2022, Gynecologic Oncology.

[13]  B. Monk,et al.  A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45) , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  I. Ray-Coquard,et al.  201 Homologous recombination deficiency testing in advanced ovarian cancer: description of the ENGOT HRD European initiative , 2021, Ovarian cancer.

[15]  I. Soubeyran,et al.  Concordance between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial. , 2020, Journal of the National Cancer Institute.

[16]  François-Clément Bidard,et al.  ShallowHRD: detection of homologous recombination deficiency from shallow whole genome sequencing , 2020, Bioinform..

[17]  F. Marmé,et al.  Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. , 2019, The New England journal of medicine.

[18]  B. Monk,et al.  Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. , 2019, The New England journal of medicine.

[19]  Gabe S. Sonke,et al.  Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer , 2018, The New England journal of medicine.

[20]  E. Bongaerts,et al.  Manuscript , 2018 .

[21]  James X. Sun,et al.  Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[22]  J. Reis-Filho,et al.  Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes , 2017, Nature Communications.

[23]  E. Lander,et al.  A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer , 2017, Nature Genetics.

[24]  E. Birney,et al.  HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures , 2017, Nature Medicine.

[25]  Tatiana Popova,et al.  Ovarian Cancers Harboring Inactivating Mutations in CDK12 Display a Distinct Genomic Instability Pattern Characterized by Large Tandem Duplications. , 2016, Cancer research.

[26]  A. Vincent-Salomon,et al.  Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. , 2012, Cancer research.

[27]  G. Mills,et al.  Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer , 2012, British Journal of Cancer.

[28]  Yangho Chen,et al.  Supplementary Methods , 2012, Acta Neuropsychiatrica.

[29]  Z. Szallasi,et al.  Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. , 2012, Cancer discovery.

[30]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[31]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.